GO:0034359 mature chylomicron: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034359 mature chylomicron describes the large, triglyceride-rich lipoprotein particle that carries dietary lipids from the intestine into blood and lymph.
• Mature chylomicrons are defined by the presence of apolipoprotein C2 (APOC2), a cofactor for lipoprotein lipase (LPL), and by a mean diameter of 500 nm and density of 0.95 g/ml.
• Assembly requires microsomal triglyceride transfer protein (MTTP) and apolipoprotein B-48 (APOB-48) in enterocytes.
• After secretion, chylomicrons acquire APOC2 and other apolipoproteins in lymph and plasma, becoming mature particles capable of LPL activation.
• Defects in chylomicron assembly, secretion, or clearance cause diseases such as chylomicron retention disease, familial chylomicronemia, and dyslipidemias.
• CRISPR knockout, knock-in, and overexpression models are powerful tools to dissect the causal roles of genes such as APOC2, LPL, MTTP, and APOB in chylomicron biology.
Description
Mature chylomicrons are the largest lipoprotein particles in the circulation and serve as the primary transport vehicles for dietary (exogenous) lipids. They are assembled in the endoplasmic reticulum of intestinal enterocytes and secreted into lymph before entering the bloodstream, where they deliver triglycerides to peripheral tissues. The term GO:0034359 captures the mature, functional state of these particles, characterized by the presence of apolipoprotein C2 (APOC2) and a specific size and density. Understanding mature chylomicron biology is essential for researchers studying lipid metabolism, cardiovascular disease, and intestinal function. Dysregulation of chylomicron assembly or clearance is linked to severe metabolic disorders, making these particles a focal point for therapeutic development.
mature chylomicron At A Glance
| GO ID | GO:0034359 |
|---|---|
| GO term | mature chylomicron |
| Ontology | cellular_component |
| Synonym | none |
| Major function | Transport of exogenous (dietary) lipids from intestines to other tissues via blood and lymph |
| Defining apolipoprotein | Apolipoprotein C2 (APOC2), a cofactor for lipoprotein lipase (LPL) |
| Mean diameter | 500 nm |
| Density | 0.95 g/ml |
| Composition | Triglycerides, cholesterol, phospholipids, apolipoproteins (APOB-48, APOC2, APOE, etc.) |
What Is GO:0034359?
GO:0034359 mature chylomicron is a cellular component term describing a chylomicron particle that contains apolipoprotein C2 (APOC2), a cofactor required for lipoprotein lipase (LPL) activity, and has a mean diameter of 500 nm and a density of 0.95 g/ml. Mature chylomicrons transport exogenous (dietary) lipids from the intestines to other body tissues via the blood and lymph.
Why Is mature chylomicron Important in Cell Biology?
Mature chylomicrons are central to dietary lipid absorption and energy distribution, and their dysfunction is directly implicated in human disease. Because they are the only lipoprotein class dedicated to transporting exogenous lipids, defects in their assembly, secretion, or clearance lead to conditions such as chylomicron retention disease, familial chylomicronemia, and increased cardiovascular risk. Studying mature chylomicrons helps researchers understand intestinal lipid handling, LPL regulation, and the pathogenesis of dyslipidemias.
• Mature chylomicrons are the primary carriers of dietary triglycerides and cholesterol from the intestine to peripheral tissues.
• APOC2 on mature chylomicrons activates LPL, the rate-limiting enzyme for triglyceride hydrolysis in plasma.
• Defective chylomicron assembly causes chylomicron retention disease, a rare inherited disorder with severe fat malabsorption.
• Impaired chylomicron clearance due to LPL or APOC2 mutations leads to familial chylomicronemia and pancreatitis risk.
• Chylomicron metabolism is a key determinant of postprandial lipemia, an independent cardiovascular risk factor.
• Enterocyte-specific knockout models have revealed mitochondrial roles in dietary lipid processing.
• Mature chylomicrons are targets for gene therapy and CRISPR-based correction of lipid disorders.
• Studying chylomicrons informs development of LPL activators and APOC2 mimetics.
• Chylomicron biology intersects with insulin resistance, obesity, and metabolic syndrome.
• Advanced imaging and tracer methods allow real-time tracking of chylomicron particles in vivo.
Structure and Composition of mature chylomicron
Lipid Core and Surface Monolayer
In simple terms: Mature chylomicrons are like fat droplets wrapped in a soap-like layer that keeps them mixed in blood.
Mature chylomicrons have a hydrophobic core composed mainly of triglycerides and cholesteryl esters, surrounded by a surface monolayer of phospholipids, free cholesterol, and apolipoproteins. This structure allows the transport of water-insoluble lipids through aqueous lymph and plasma.
Apolipoprotein B-48 (APOB-48)
In simple terms: APOB-48 is the structural backbone that holds the chylomicron together.
APOB-48 is synthesized in enterocytes and is essential for the assembly and secretion of chylomicrons. It remains on the particle throughout its lifetime and serves as a structural scaffold.
Apolipoprotein C2 (APOC2)
In simple terms: APOC2 is the key that turns on the fat-burning enzyme LPL.
APOC2 is acquired by chylomicrons in the circulation and acts as an obligatory cofactor for lipoprotein lipase (LPL). Its presence defines the mature chylomicron in GO:0034359.
Other Apolipoproteins (APOE, APOC3, APOA5)
In simple terms: Other proteins on the surface fine-tune how chylomicrons are processed and cleared.
APOE mediates remnant uptake by hepatic receptors, while APOC3 inhibits LPL and APOA5 enhances LPL activity. These apolipoproteins modulate chylomicron clearance and are important research targets.
Size and Density Characteristics
In simple terms: Mature chylomicrons are the biggest and lightest lipoproteins, which makes them float in plasma.
With a mean diameter of 500 nm and density of 0.95 g/ml, mature chylomicrons are the largest and least dense lipoproteins. These physical properties allow their isolation by ultracentrifugation and are used to distinguish them from VLDL and other particles.
Key Genes Involved in GO:0034359 mature chylomicron
The following genes encode proteins that are critical for the assembly, secretion, maturation, and clearance of mature chylomicrons.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APOB | Structural apolipoprotein B-48; essential for chylomicron assembly | Mutations cause abetalipoproteinemia; target for KO and knock-in studies |
| MTTP | Microsomal triglyceride transfer protein; loads lipids onto APOB | Defects cause abetalipoproteinemia; key for assembly research |
| APOC2 | Cofactor for lipoprotein lipase; defines mature chylomicron | Mutations cause familial chylomicronemia; target for overexpression and point mutation |
| LPL | Hydrolyzes triglycerides in chylomicrons | Central to clearance; KO models develop severe hypertriglyceridemia |
| APOC3 | Inhibits LPL and hepatic remnant uptake | Target for antisense and CRISPR therapy |
| APOA5 | Enhances LPL activity | Genetic variants affect triglyceride levels |
| APOE | Mediates remnant clearance via hepatic receptors | Isoforms affect cardiovascular risk |
| SAR1B | GTPase required for COPII-mediated chylomicron secretion | Mutations cause chylomicron retention disease |
| GPIHBP1 | Endothelial platform for LPL | Defects cause hypertriglyceridemia |
| LMF1 | Lipase maturation factor 1; required for LPL folding | Mutations cause combined lipase deficiency |
| CREB3L3 | Transcription factor regulating lipid genes | Modulates chylomicron production |
| HNF4A | Nuclear receptor controlling enterocyte lipid metabolism | Knockout alters chylomicron secretion |
| CD36 | Fatty acid transporter; affects chylomicron production | KO models show reduced lipid absorption |
| DGAT1 | Diacylglycerol acyltransferase; synthesizes triglycerides | KO reduces chylomicron secretion |
| MOGAT2 | Monoacylglycerol acyltransferase; intestinal triglyceride synthesis | KO alters lipid handling |
| FABP2 | Intestinal fatty acid binding protein | Polymorphisms affect lipid absorption |
How Is mature chylomicron Regulated?
Mature chylomicron levels are regulated at multiple levels: transcription of APOB and MTTP is controlled by nutrient and hormonal signals; secretion requires SAR1B and COPII vesicles; and clearance depends on LPL activity, which is regulated by APOC2, APOC3, APOA5, and GPIHBP1. Mitochondrial function in enterocytes also influences dietary lipid processing and chylomicron secretion.
mature chylomicron and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SAR1B | Chylomicron retention disease | Knockout in intestinal organoids or Caco-2 cells |
| LPL | Familial chylomicronemia syndrome | Knockout mouse or knock-in of patient mutations |
| APOC2 | Familial chylomicronemia | Overexpression and point mutation models |
| MTTP | Abetalipoproteinemia | Knockout in HepG2 or enterocytes |
| APOB | Abetalipoproteinemia; hypobetalipoproteinemia | Knock-in of truncating mutations |
Chylomicron Retention Disease (CRD)
Chylomicron retention disease is caused by mutations in SAR1B, leading to defective secretion of chylomicrons from enterocytes. Patients present with fat malabsorption, failure to thrive, and hypocholesterolemia.
Familial Chylomicronemia Syndrome (FCS)
FCS results from loss-of-function mutations in LPL, APOC2, APOA5, GPIHBP1, or LMF1, causing severe hypertriglyceridemia and recurrent pancreatitis. Mature chylomicrons accumulate because LPL cannot hydrolyze their triglycerides.
Abetalipoproteinemia
Mutations in MTTP or APOB prevent chylomicron assembly, leading to fat malabsorption, steatorrhea, and vitamin deficiencies. This highlights the essential role of these genes in mature chylomicron formation.
Cardiovascular Risk and Postprandial Lipemia
Elevated postprandial chylomicron remnants are associated with increased cardiovascular risk. Studying mature chylomicron metabolism helps identify therapeutic targets for dyslipidemia.
From mature chylomicron-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does APOC2 deficiency impair LPL activation? | APOC2 knockout cell line or mouse |
| How do SAR1B mutations affect chylomicron secretion? | Knock-in of patient mutations in Caco-2 cells |
| Can overexpression of APOA5 enhance chylomicron clearance? | Overexpression cell model |
| What is the role of mitochondrial genes in dietary lipid processing? | Enterocyte-specific knockout |
| Does a candidate gene regulate APOB secretion? | CRISPR knockout followed by APOB ELISA |
| Can a tagged APOC2 be tracked in live cells? | Knock-in of fluorescent tag |
How to Study the mature chylomicron Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Ultracentrifugation | Density-based separation of lipoproteins | Isolation of mature chylomicrons |
| Dynamic light scattering | Particle size distribution | Confirming 500 nm diameter |
| CRISPR knockout screening | Gene essentiality for chylomicron secretion | Identifying novel regulators |
| Proteomics | Apolipoprotein composition | Comparing normal vs. disease models |
| Lipidomics | Triglyceride and phospholipid species | Assessing lipid cargo |
| Fluorescent labeling | Particle tracking in vivo | Clearance studies |
| ELISA | APOB or APOC2 concentration | Quantifying secretion |
| Transmission electron microscopy | Particle morphology | Visualizing chylomicrons |
Lipoprotein Isolation and Characterization
Ultracentrifugation and gel filtration are used to isolate mature chylomicrons based on their density and size. Dynamic light scattering and electron microscopy confirm the 500 nm diameter.
CRISPR Screening for Chylomicron Regulators
Genome-wide CRISPR knockout screens in enterocyte-like cells can identify genes required for APOB secretion or lipid droplet formation. Hits are validated by targeted knockout and lipid flux assays.
Proteomics and Lipidomics
Mass spectrometry-based proteomics identifies apolipoprotein composition, while lipidomics quantifies triglyceride and phospholipid species in mature chylomicrons. These methods reveal changes in disease models.
In Vivo Imaging and Tracer Studies
Fluorescently labeled chylomicrons or radioactive tracers track particle clearance in animal models. This provides dynamic information on mature chylomicron metabolism.
How CRISPR Can Be Used to Study GO:0034359 mature chylomicron
Knockout
CRISPR knockout of genes such as APOC2, LPL, or MTTP in cell models abolishes mature chylomicron function, providing causal evidence for their roles. Knockout enterocytes show defective lipid secretion.
Point Mutation
Introducing patient-specific point mutations (e.g., in APOC2 or LPL) via CRISPR allows study of loss-of-function or dominant-negative effects on chylomicron maturation. These models mimic familial chylomicronemia.
Knock-in
Knock-in of tagged APOB or APOC2 enables live-cell imaging and tracking of mature chylomicrons. Knock-in of disease mutations in SAR1B recapitulates chylomicron retention disease.
Overexpression
CRISPR activation or cDNA overexpression of APOA5 or APOC2 enhances chylomicron clearance and can rescue LPL deficiency in models. Overexpression studies help identify rate-limiting steps.
How EDITGENE Supports mature chylomicron Research
Researchers studying mature chylomicron-related genes often need to determine whether a candidate gene is causally involved in particle assembly, secretion, or clearance. EDITGENE provides custom CRISPR cell models to test these hypotheses with precision.
Contact EDITGENE today to design your custom CRISPR model for mature chylomicron research.
Frequently Asked Questions About mature chylomicron
What is a mature chylomicron?
A mature chylomicron is a large lipoprotein particle that contains APOC2, has a mean diameter of 500 nm and density of 0.95 g/ml, and transports dietary lipids from the intestine to other tissues.
What genes are involved in mature chylomicron formation?
Key genes include APOB, MTTP, SAR1B, APOC2, LPL, APOC3, APOA5, and APOE.
What is the function of APOC2 in chylomicrons?
APOC2 is a cofactor for lipoprotein lipase (LPL) and is required for the maturation and triglyceride hydrolysis of chylomicrons.
How is mature chylomicron defined in GO?
GO:0034359 defines it as a chylomicron that contains APOC2 and has a mean diameter of 500 nm and density of 0.95 g/ml.
What diseases are associated with defective chylomicrons?
Chylomicron retention disease, familial chylomicronemia, and abetalipoproteinemia are linked to defects in chylomicron assembly or clearance.
How can I study mature chylomicrons in the lab?
Methods include ultracentrifugation, dynamic light scattering, CRISPR knockout models, proteomics, and in vivo imaging.
What is the role of LPL in chylomicron metabolism?
LPL hydrolyzes triglycerides in mature chylomicrons, releasing fatty acids for tissue uptake.
Can CRISPR be used to model chylomicron diseases?
Yes, CRISPR knockout, knock-in, and point mutation models can recapitulate monogenic lipid disorders.
What is chylomicron retention disease?
It is a rare disorder caused by SAR1B mutations, leading to defective chylomicron secretion from enterocytes.
Why are mature chylomicrons important for cardiovascular health?
Elevated chylomicron remnants are associated with increased cardiovascular risk and postprandial lipemia.
Conclusion
Mature chylomicrons are essential for dietary lipid transport and represent a critical node in metabolic health and disease. Understanding their assembly, composition, and regulation provides insights into rare genetic disorders and common dyslipidemias. Advanced CRISPR models and multi-omics approaches continue to uncover new regulators of this dynamic particle.
References
- 1. Feingold KR et al.. 2000. Introduction to Lipids and Lipoproteins.. PMID: 26247089
- 2. Feingold KR. 2022. Lipid and Lipoprotein Metabolism.. Endocrinol Metab Clin North Am 51(3):437-458 PMID: 35963623
- 3. Adam MP et al.. 1993. Chylomicron Retention Disease.. PMID: 35344313
- 4. Moschandrea C et al.. 2024. Mitochondrial dysfunction abrogates dietary lipid processing in enterocytes.. Nature 625(7994):385-392 PMID: 38123683
- 5. Feingold KR et al.. 2000. Genetics and Dyslipidemia.. PMID: 27809445
- 6. Zhang H. 2004. (64)Cu-DTPA-CLIO-VT680.. PMID: 20641719
- 7. Wu SA et al.. 2021. Lipoprotein Lipase and Its Regulators: An Unfolding Story.. Trends Endocrinol Metab 32(1):48-61 PMID: 33277156
- 8. Ramasamy I. 2014. Recent advances in physiological lipoprotein metabolism.. Clin Chem Lab Med 52(12):1695-727 PMID: 23940067
